Breast Cancer Now media statements
Breast Cancer Now flags concerns over findings of final PAC Report
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Breast Cancer Now responds to research about detecting breast cancer from fingertip smears
In response to research, published in Scientific Reports*, about detecting breast cancer from fingertip smears, Dr Kotryna Temcinaite, senio...
Breast Cancer Now responds to Cancer Research UK’s estimate that the number of people diagnosed with cancer will ‘rise by a third by 2040’
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to research about the benefits of exercise
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research published in JAMA Open Network about the benefi...
We respond to research about radiotherapy and long-term breast cancer survival
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has responded to research presented at the 13th European Breast Cancer Co...
We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research presented at the 13th European Breast Cancer Co...
We respond to latest NHSE Cancer Wait Times data
Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, has commented on the latest NHS England Ca...
We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS wa...
We respond to the launch of the first UK proton beam therapy trial for breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, has commented on the new estimates.
We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on NICE'S decision to approve trastuzumab deruxtecan for use on ...
We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.